Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Cardiovascular Safety of One-Year Escitalopram Therapy in Clinically Nondepressed Patients With Acute Coronary Syndrome: Results From the DEpression in Patients With Coronary ARtery Disease (DECARD) Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Loss of autoregulation of blood flow in subcutaneous tissue in juvenile diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Lung Ultrasound Findings Associated With COVID-19 ARDS, ICU Admission, and All-Cause Mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Recovery of Cardiac Function Following COVID-19 - ECHOVID-19: A Prospective Longitudinal Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cardiac arrhythmias in patients hospitalized with COVID-19: The ACOVID study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
: Selective serotonin reuptake inhibitors are commonly used for treatment of depression in patients with cardiac diseases. However, evidence of cardiovascular (CV) safety from randomized trials is based on studies of no longer than 6-month duration. We examined the CV safety of 1-year treatment with Selective serotonin reuptake inhibitor escitalopram compared with placebo in patients with recent acute coronary syndrome (ACS).
OriginalsprogEngelsk
TidsskriftJournal of Cardiovascular Pharmacology
Vol/bind60
Udgave nummer4
Sider (fra-til)397-405
Antal sider9
ISSN0160-2446
DOI
StatusUdgivet - 2012

ID: 36396218